Skip to main content

Aptensio XR

(methylphenidate XR)

Full Prescribing Information DailyMed Drug Information

Forms/Strengths

  • Capsules: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg 

Dosing

  • Age: ≥ 6 y/o
  • Onset: ~ 60-120 min
  • Duration: 8-12 hours
  • Release Profile: 40% IR, 60% ER
  • Considerations: Capsules may be swallowed whole or opened, and the entire contents can be sprinkled on applesauce.
  • Initial Dose: 10 mg
  • Titration: 10 mg weekly
  • Max Dose: 60 mg/day

Quick Facts

  • Blocks reuptake of dopamine and norepinephrine via DAT and NET inhibition, increasing synaptic levels primarily in prefrontal cortex for improved attention and impulse control
  • Biphasic release: ~50% immediate-release beads, ~50% delayed-release beads for rapid onset and sustained effect
  • Common side effects include appetite suppression, insomnia, and mild cardiovascular changes
  • Black box warning: Potential for abuse, misuse, and dependence; sudden death reported in patients with structural cardiac abnormalities
  • Monitor growth in children; caution in patients with tics, bipolar disorder, or psychosis
  • Not for use within 14 days of MAOIs due to hypertensive crisis risk

Indications

  •  ADHD (ICD-10: F90.0)

Off-Label Uses

  • Narcolepsy (ICD-10: G47.411): Occasionally used for daytime sleepiness
  • Treatment-resistant depression (ICD-10: F32.x, F33.x): Adjunct for augmentation in select cases

How to Take

  • Administration: Once daily in the morning with or without food; high-fat meals may delay Tmax and increase exposure; do not crush/chew capsules; if unable to swallow, sprinkle entire contents on ≤1 tablespoon applesauce and swallow immediately
  • Missed Dose: Take next dose as scheduled; do not double dose
  • Discontinuation/Tapering: May discontinue abruptly after short-term use; taper if long-term (>4 weeks) or high-dose to minimize rebound symptoms

Side Effects

  • Common:
    • Appetite/weight loss
    • Insomnia, headache
    • Abdominal pain, nausea, dry mouth
    • Increased heart rate/blood pressure, anxiety/irritability
  • Serious:
    • Black box warning: Drug abuse/dependence; assess risk prior to use
    • Cardiovascular: Sudden death/myocardial infarction in patients with cardiac disease, priapism
    • Psychiatric: Psychosis, mania, aggression, suicidal ideation
    • Peripheral vasculopathy (e.g., Raynaud's): Digital ulceration
    • Hypersensitivity: Rash, anaphylaxis

Monitoring / Labs

  • Baseline and periodic: Heart rate, blood pressure, weight/height (pediatrics)
  • Psychiatric status for new/worsening symptoms
  • Growth parameters every 3-6 months in children; consider drug holiday
  • CBC, CMP if long-term use; signs of abuse/diversion

Education

  • When to Call the Doctor:

    • Severe mood changes, aggression, or suicidal thoughts.
    • Chest pain, rapid heartbeat, shortness of breath (cardiovascular concerns).
    • Uncontrolled movements, tics, or worsening anxiety.
    • Numbness, coldness, or color changes in fingers or toes (circulatory issues).
    • Unexplained weight loss or delayed growth in pediatric patients.
  • Safety Tips:

    • Monitor blood pressure and heart rate, especially in patients with cardiovascular risk.
    • Use caution in patients with anxiety, bipolar disorder, or psychosis, as symptoms may worsen.
    • Avoid caffeine and other stimulants, which may amplify side effects.
    • Ensure adequate hydration and nutrition, as appetite suppression is common.
    • Tapering may be required if discontinuing after long-term use.
  • Parent Tips for Pediatric Patients:

    • Encourage a nutrient-dense diet to counteract appetite suppression.
    • Administer in the morning before school for optimal effect.
    • Monitor school performance and behavioral changes.
    • Observe for sleep disturbances; adjust timing if necessary.
    • Communicate regularly with teachers and caregivers about medication effects.

Additional Information

  • Contraindications:

    • Hypersensitivity to methylphenidate
    • Concurrent/use within 14 days of MAOIs
    • Glaucoma, severe hypertension, symptomatic cardiac disease
  • Pregnancy: Category C (older); limited human data—use if benefit outweighs risk; neonatal withdrawal possible
  • Lactation: Present in breast milk; weigh risks (irritability, reduced weight gain in infant)
  • Drug Interactions:
    • MAOIs/serotonergics: Hypertensive crisis/serotonin syndrome
    • CYP2D6 inhibitors (e.g., bupropion): Increased methylphenidate levels
    • Acidifiers (e.g., vitamin C): Decreased absorption; alkalinizers (e.g., antacids): Increased absorption
    • Pressors (e.g., alpha-agonists): Potentiated hypertension
    • Alcohol: Accelerated release from capsules

References

  1. FDA. Concerta (methylphenidate HCl) Prescribing Information, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021121s042lbl.pdf
  2. DailyMed. Methylphenidate Hydrochloride Extended-Release Capsules, 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=example (generic XR capsules)
  3. UpToDate. Methylphenidate: Drug information, 2025. https://www.uptodate.com/contents/methylphenidate-drug-information
  4. American Academy of Pediatrics. ADHD Clinical Practice Guideline, 2021. https://publications.aap.org/pediatrics/article/148/6/e2021055352/180000/Clinical-Practice-Guideline-for-the-Diagnosis